Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults

Abstract Background Enzyme replacement therapy with olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is indicated for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in children and adults. An ongoing, open-label, long-term study (NCT02004704) a...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Robin H. Lachmann, George A. Diaz, Melissa P. Wasserstein, Nicole M. Armstrong, Abhimanyu Yarramaneni, Yong Kim, Monica Kumar
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2023-04-01
Цуврал:	Orphanet Journal of Rare Diseases
Нөхцлүүд:	Olipudase alfa Recombinant human acid sphingomyelinase Acid sphingomyelinase deficiency Niemann-Pick disease type B and type A/B
Онлайн хандалт:	https://doi.org/10.1186/s13023-023-02700-x
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!